Wealth Minerals (OTCMKTS:WMLLF) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
This is a breakdown of recent ratings and target prices for Wealth Minerals and Opiant Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opiant Pharmaceuticals has a consensus target price of $42.00, indicating a potential upside of 186.69%. Given Opiant Pharmaceuticals’ higher probable upside, analysts clearly believe Opiant Pharmaceuticals is more favorable than Wealth Minerals.
This table compares Wealth Minerals and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
0.0% of Wealth Minerals shares are held by institutional investors. Comparatively, 18.6% of Opiant Pharmaceuticals shares are held by institutional investors. 37.9% of Opiant Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Wealth Minerals and Opiant Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Opiant Pharmaceuticals||$18.45 million||3.05||$6.58 million||$2.94||4.98|
Opiant Pharmaceuticals has higher revenue and earnings than Wealth Minerals.
Risk & Volatility
Wealth Minerals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Opiant Pharmaceuticals beats Wealth Minerals on 5 of the 9 factors compared between the two stocks.
Wealth Minerals Company Profile
Wealth Minerals Ltd., a junior mineral resource exploration company, engages in the acquisition, exploration, and development of mineral properties in Chile, British Columbia, Peru, and Mexico. The company primarily explores for lithium, as well as for precious metal, copper, gold, and silver deposits. Its principal project is the Atacama project that comprises 144 exploration concessions in the Atacama Salar in Region II of Antofagasta, northern Chile. The company was founded in 1994 and is headquartered in Vancouver, Canada.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Receive News & Ratings for Wealth Minerals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wealth Minerals and related companies with MarketBeat.com's FREE daily email newsletter.